|
本帖最后由 jyqian 于 2021-1-29 18:17 编辑
立刻搜了一下
The Commission is negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (400 million doses ), BioNTech-Pfizer 600 million doses, CureVac (405 million doses) and Moderna (160 million doses). The Commission has concluded exploratory talks with the pharmaceutical company Novavax with a view to purchasing up to 200 million doses and with Valneva with a view to purchase up to 60 million doses.
只要三期数据好,欧盟应该会立刻追加购买的吧。就像现有的这两款。Novavax 三期结果应该两月份最晚三月要出来了吧
我觉得跟UK争论阿斯利康疫苗对老人保护是次要的,关键是阿斯利康疫苗对变种病毒到底有没有用啊,好像没有看到报道啊。Moderna就研究过说他家的对变种病毒目前还是有用的,但是效力下降了,所以会研究给已经打过的人增加一剂booster,那阿斯利康这个腺病毒疫苗就没法加强booster的啊,难道这不是更要紧的问题么。现在我们附近科隆都有幼儿园里有英国变异病毒传播了,已经进入社区传播阶段了,2月中旬以后肯定要逐步放开一点封锁,可以预见再过两个月变种病毒将会成为传播的主流,所以现在要抓紧增加购买和增产能对付变异病毒的疫苗啊
|
|